Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy

Embryos can achieve immune tolerance, yet the underlying mechanisms remain incompletely understood. Here, we demonstrate that pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), secrete extracellular vesicles (EVs) that markedly outperform mesenchymal stem cell (MSC)–derived EVs in suppressing pro-inflammatory cytokine secretion, inhibiting activated T-cell proliferation, and inducing regulatory T-cell (Treg) formation through CDK8 downregulation. Nuclear magnetic resonance (NMR) analysis reveals distinct molecular fingerprints of PSC EVs compared to those of MSC EVs. Moreover, comparative analyses show that PSC EVs contain unique proteins and microRNAs, such as the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family, which are not found in MSC EVs, as determined by proteomic profiling and microRNA sequencing. Notably, the dynamic suspension culture of PSC aggregates significantly increases EV yield, offering a scalable and reproducible source superior to other cell sources. To evaluate their therapeutic potential, we employed an antigen-specific type 1 diabetes model and found that two local injections of iPSC EVs, particularly when delivered via a biomaterial scaffold, significantly enhanced diabetes-free survival. These treatments increased Treg populations in draining lymph nodes, induced systemic immunomodulation, and preserved β-cell mass from immune-mediated destruction. The immunomodulatory capability of PSC EVs suggests broad applications in treating autoimmune diseases and supporting stem cell-derived cell therapies by promoting immune tolerance. Their scalability, consistency, and superior therapeutic properties position PSC EVs as a compelling platform for next-generation immunotherapies and cell-based treatment strategies.

Authors

Institutions

Publication Details

Journal
Nature Nanotechnology
Published
2026-11-18
DOI
https://doi.org/10.1038/s41565-026-02320-z
Citations
3
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
3.36

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy

Zhen Gu, Reza Ardehali, Graciel Diamante, Fatemeh Sadat Majedi et al.
3 citations
Nature Nanotechnology
Extracellular vesicles in disease
3.36
article

Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy

Zhen Gu, Reza Ardehali, Graciel Diamante, Fatemeh Sadat Majedi, Manish J. Butte, Louis‐S. Bouchard, Yutong Wu, Xiao Han, Peter C. Butler, Xia Yang, Xiaojun Lance Lian, Mohammad Mahdi Hasani‐Sadrabadi, Song Li, Li Yang, Jianyi Zhang, In Sook Ahn
article en
3 citations

Abstract

Embryos can achieve immune tolerance, yet the underlying mechanisms remain incompletely understood. Here, we demonstrate that pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), secrete extracellular vesicles (EVs) that markedly outperform mesenchymal stem cell (MSC)–derived EVs in suppressing pro-inflammatory cytokine secretion, inhibiting activated T-cell proliferation, and inducing regulatory T-cell (Treg) formation through CDK8 downregulation. Nuclear magnetic resonance (NMR) analysis reveals distinct molecular fingerprints of PSC EVs compared to those of MSC EVs. Moreover, comparative analyses show that PSC EVs contain unique proteins and microRNAs, such as the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family, which are not found in MSC EVs, as determined by proteomic profiling and microRNA sequencing. Notably, the dynamic suspension culture of PSC aggregates significantly increases EV yield, offering a scalable and reproducible source superior to other cell sources. To evaluate their therapeutic potential, we employed an antigen-specific type 1 diabetes model and found that two local injections of iPSC EVs, particularly when delivered via a biomaterial scaffold, significantly enhanced diabetes-free survival. These treatments increased Treg populations in draining lymph nodes, induced systemic immunomodulation, and preserved β-cell mass from immune-mediated destruction. The immunomodulatory capability of PSC EVs suggests broad applications in treating autoimmune diseases and supporting stem cell-derived cell therapies by promoting immune tolerance. Their scalability, consistency, and superior therapeutic properties position PSC EVs as a compelling platform for next-generation immunotherapies and cell-based treatment strategies.

Nature Nanotechnology
Tulane University (US), Pennsylvania State University (US), University of California, Los Angeles (US), Czech Academy of Sciences (CZ), Cornell University (US), University of Alabama at Birmingham (US), Broad Center (US), Czech Academy of Sciences, Institute of Physiology (CZ), UCLA Jonsson Comprehensive Cancer Center (US), Zhejiang University (CN)
California Institute for Regenerative Medicine, Juvenile Diabetes Research Foundation United States of America, National Institutes of Health, University of California, Los Angeles, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles
Good health and well-being
Openalex Percentile: Top 10%
Extracellular vesicles in disease
3.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon